Complicated parapneumonic effusion and empyema thoracis: Microbiology and predictors of adverse outcomes

Hong Kong Medical Journal

Volumn 13, Issue 3, 2007, Pages 178-186

  Tsang, K Y ^a   Leung, W S ^a   Chan, Veronica L ^a   Lin, Alsa W L ^a   Chu, C M ^a  

^a UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

Empyema, pleural; Fibrinolytic agents; Guidelines; Pleural effusion; Pneumonia; Thoracic cavity

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; STREPTOKINASE; SULPERAZON; SULTAMICILLIN; TIMENTIN; UROKINASE;

ADVERSE OUTCOME; AGE DISTRIBUTION; BACTERIUM ISOLATE; BACTEROIDES; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FIBRINOLYTIC THERAPY; HONG KONG; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; KLEBSIELLA PNEUMONIAE; MICROBIOLOGICAL EXAMINATION; MORTALITY; OUTCOME ASSESSMENT; PEPTOSTREPTOCOCCUS; PLEURA EFFUSION; PLEURA EMPYEMA; PLEURA FLUID; PRACTICE GUIDELINE; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SEX RATIO; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS MILLERI; SURGICAL DRAINAGE; SURVIVAL; TREATMENT DURATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEROIDES; DRUG UTILIZATION REVIEW; EMPYEMA, PLEURAL; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HONG KONG; HOSPITAL MORTALITY; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; PEPTOSTREPTOCOCCUS; PLEURAL EFFUSION; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK FACTORS; STREPTOCOCCUS MILLERI GROUP; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34250338093     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
2. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33.
3. File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001.
4. Death rates for leading causes of death (based on ICD 10th version): 2001 - 2005. HKSAR Centre for Health Protection website: http://www.chp.gov.hk/ data153b.html?lang=en&cat=4&dns_sumID=117&id=27&pid=10&ppid= . Accessed 1 Feb 2006.
5. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980;69:507-12.
6. Heffner JE, McDonald J, Barbieri C, Klein J. Management of parapneumonic effusions. An analysis of physician practice patterns. Arch Surg 1995;130:433-8.
7. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000;118:1158-71.
8. Davies CW, Kearney SE, Gleeson FV, Davies RJ. Predictors of outcome and long-term survival in patients with pleural infection. Am J Respir Crit Care Med 1999;160:1682-7.
9. Ferguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR. The clinical course and management of thoracic empyema. QJM 1996;89:285-9.
10. Davies CW, Gleeson FV, Davies RJ; Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of pleural infection. Thorax 2003;58(Suppl 2):18S-28S.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
13. National Committee of Clinical Laboratory Standards. Performance standards for antimicroibal susceptibility testing: 9th informational supplement. Villanova, PA: National Committed for Clinical Laboratory Standards; 1999.
14. Menendez R, Torres A, Zalacaín R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005;172:757-62.
15. Maskell NA. Davies CW, Nunn AJ, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74.
16. Sahn SA. Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas. Thorax 1998;53(Suppl 2):65S-72S.
17. Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991;144:187-94.
18. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997;52:416-21.
19. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med 1999;159:37-42.
20. Bouros D, Schiza S, Patsourakis G, Chalkiadakis G, Panagou P, Siafakas NM. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med 1997;155:291-5.
21. Thomson AH, Hull J, Kumar MR, Wallis C, Balfour Lynn IM. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002;57:343-7.
22. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004;170:49-53.
23. Maskell NA, Davies RJ. Effusions from parapneumonic infection and empyema. In: Light RW, Lee YC, editors. Textbook of pleural diseases. London: Arnold; 2003:310-28.
24. Heffner JE. Multicenter trials of treatment for empyema - after all these years. N Engl J Med 2005;352:926-8.
25. Bhattacharyya N, Umland ET, Kosloske AM. A bacteriologic basis for the evolution and severity of empyema. J Pediatr Surg 1994;29:667-70.
26. Chapman SJ, Davies RJ. Recent advances in parapneumonic effusion and empyema. Curr Opin Pulm Med 2004;10:299-304.
27. Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. Chest 1993;103:1502-7.
28. Bartlett JG, Gorbach SL, Thadepalli H, Finegold SM. Bacteriology of empyema. Lancet 1974;1:338-40.
29. Wang JL, Chen KY, Fang CT, Hsueh PR, Yang PC, Chang SC. Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes. Clin Infect Dis 2005;40:915-22.
30. Chen KY, Hsueh PR, Liaw YS, Yang PC, Luh KT. A 10-year experience with bacteriology of acute thoracic empyema: emphasis on Klebsiella pneumoniae in patients with diabetes mellitus. Chest 2000;117:1685-9.
31. Eastham KM, Freeman R, Kearns AM, et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax 2004;59:522-5.
32. Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics 2004;113:1735-40.
33. Finland M, Barnes MW. Changing ecology of acute bacteria empyema: occurrence and mortality at Boston City Hospital during 12 selected years from 1935 to 1972. J Infect Dis 1978;137:274-91.